AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03571321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: For patients that have cluster of differentiation antigen 20 positive (CD20+) disease only.~Remission consolidation regimen:~* 375 mg/m2 IV on Days 1, 8, 29 and 36~Interim maintenance regimen:~* 375 mg/m2 IV on Days 1 and 11~Delayed Intensification regimen:~* 375 mg/m2 IV on Days 1 and 8
Study NCT03571321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (Intrathecal Administration)
Description: Drug is given through a needle which is inserted in one of the spaces between the bones in the lower back (intrathecal \[IT\] administration).~Remission consolidation regimen:~* 15 mg on Days 1, 8, 15, and 22~Interim maintenance regimen:~* 15 mg on Days 1 and 31~Delayed Intensification regimen:~* 15 mg on Days 1, 29, and 36~Maintenance Therapy:~* 15 mg on Day 1~* 15 mg on Day 29 (First 4 courses only)
Study NCT03571321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (Intravenous Administration)
Description: Interim maintenance regimen:~* 100 mg/m2 IV on Days 1, 11, 21, 31, and 41
Study NCT03571321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Taken by mouth or given by IV infusion.~Delayed Intensification regimen:~* 10 mg/m2 per day (divided into 2 doses) on Days 1-7 and 15-21~Maintenance Therapy:~* 6 mg/m2 per day (divided into 2 doses) on Days 1-5, 29-33, and 57-61
Study NCT03571321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Delayed Intensification regimen:~* 25 mg/m2 IV on Days 1, 8, 15
Study NCT03571321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Taken by mouth at least 1 hour after evening meal.~Delayed Intensification regimen:~* 60 mg/m2 on Days 29-42
Study NCT03571321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate Oral Product
Description: Taken by mouth.~Maintenance Therapy:~* 20 mg/m2 weekly (on Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78)~* Not given on Day 29 of first 4 courses (on days when IT Methotrexate is given\]
Study NCT02323932 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Perception of correct intonation identification
Description: The amount of change in the fundamental frequency that was required in order to identify a question
Study NCT01721473 — intervention group
Intervention type: OTHER
Intervention: positron emission tomography scan
Description: 2-FA positron emission tomography scan
Study NCT02701842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ImPACT Online/Paper Pencil Tests
Study NCT02701842 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ImPACT Online
Study NCT01338142 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CCC
Description: 600 mg (2 capsules of 300 mg) for oral use of 480 mg CCC (192 mg elemental calcium) intrinsically labeled with 15 mg 44Ca and 120 mg of inactive filler, sucrose.~1.5 mg of 42Ca labeled CaCl2 through IV injection
Study NCT01338142 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACC
Description: 600 mg (2 capsules of 300 mg) for oral use containing 600 mg ACC (192 mg elemental calcium) intrinsically labeled with 15 mg 44Ca 1.5 mg of 42Ca labeled CaCl2 through IV injection
Study NCT03813771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benepali
Description: Benepali will be adminstered subcutaneously at a dose of 50mg weekly and discontinued at the primary endpoint (24 weeks).
Study NCT03813771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfasalazine
Description: Sulfasalazine will be added at follow up visits (T2T care) if the subject fails to achieve low disease activity,administered orally at a dose of 1g twice daily.
Study NCT03813771 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sulfasalazine
Description: Sulfasalazine will be added at follow up visits (T2T care) if the subject fails to achieve low disease activity,administered orally at a dose of 1g twice daily.
Study NCT03813771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate will be administered orally at a starting dose of 15mg weekly. It may be increased in line with T2T care (to a maximum of 25mg) over the 24 weeks.
Study NCT03813771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate will be administered orally at a starting dose of 15mg weekly. It may be increased in line with T2T care (to a maximum of 25mg) over the 24 weeks.
Study NCT03813771 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Methotrexate
Description: Methotrexate will be administered orally at a starting dose of 15mg weekly. It may be increased in line with T2T care (to a maximum of 25mg) over the 24 weeks.
Study NCT03813771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine will be added at follow up visits (T2T care) if the subject fails to achieve low diseaseactivity, administered at a dose of 200mg daily.
Study NCT03813771 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine will be added at follow up visits (T2T care) if the subject fails to achieve low diseaseactivity, administered at a dose of 200mg daily.
Study NCT01720212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM178
Description: oral
Study NCT03163810 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erchonia Verju Laser
Description: The Erchonia Verju Laser is applied 2 times a week to the front and back of the waist, hips and upper abdomen for 30 minutes each time over 8 to 12 weeks.
Study NCT03163810 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erchonia EVRL Laser
Description: The Erchonia EVRL Laser is applied under the right ribcage angled towards the liver for 10 minutes, one time per week over the same 8 to 12 weeks as the Verju Laser is administered.
Study NCT02223182 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Viaskin Milk 150 mcg
Description: Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 150 mcg cow's milk proteins.
Study NCT02223182 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Viaskin Milk 300 mcg
Description: Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 300 mcg cow's milk proteins.
Study NCT02223182 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Viaskin Milk 500 mcg
Description: Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 500 mcg cow's milk proteins.
Study NCT02223182 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Viaskin Placebo
Description: Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing a matching placebo formulation.
Study NCT03663712 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: TVEC is an oncolytic, genetically modified virus designed to reproduce in tumor tissue and stimulate your immune system to attack the tumor cells
Study NCT00924989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-906
Description: Administered orally
Study NCT00924989 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered orally
Study NCT02930876 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Set of muscle strengthening exercises of all major muscle groups, guided by physiotherapists.
Study NCT00252629 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Nasal CPAP treatment during sleep
Description: After documenting sleep disordered breathing, GWS subject gets randomized to receive either a therapeutic nasal CPAP or a sham nasal CPAP treatment during sleep, GWS symptoms ( fatigue, pain, and cognitive dysfunction) were assessed by a baseline questionnaires and at 3 week period whether on sham or therapeutic CPAP. The change of symptoms in each group will be compared.
Study NCT00252629 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nasal CPAP treatment during sleep
Description: After documenting sleep disordered breathing, GWS subject gets randomized to receive either a therapeutic nasal CPAP or a sham nasal CPAP treatment during sleep, GWS symptoms ( fatigue, pain, and cognitive dysfunction) were assessed by a baseline questionnaires and at 3 week period whether on sham or therapeutic CPAP. The change of symptoms in each group will be compared.
Study NCT00745173 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Premarin
Study NCT04069078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyoscine Butylbromide 20 Mg/mL Solution for Injection Ampoule
Description: Patients will receive IV study solution which is hyoscine butylbromide 20 mg in 1 ml one minute after spinal anaesthesia
Study NCT04069078 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Patients will receive 1 ml of IV normal saline as a placebo one minute after spinal anesthesia
Study NCT02717845 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ellipse
Description: diagnostic CT scan imaging
Study NCT02717845 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tomofix
Description: diagnostic CT scan imaging
Study NCT00684580 — intervention group
Intervention type: OTHER
Intervention: Data Collection
Description: Continuing review of outcomes and late toxicities
Study NCT03606395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NV-5138
Description: single ascending dose
Study NCT03606395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Placebo liquid solution to mimic NV-5138
Study NCT01936727 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: cataract surgery
Study NCT01184131 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mentor Training
Description: Four 2 hour sessions of Mentor Training
Study NCT03750695 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: One acute exercise session of resistance exercise (40 minutes including 3 sets of 8-10 repetitions at the participant's 10 repetition maximum load of upper and lower extremity exercise
Study NCT03750695 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: One acute session of aerobic exercise (40 minutes of cycle ergometry exercise at 70% of VO2peak)
Study NCT03750695 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Rest
Description: 40 minutes of quiet rest in semi-recumbent position
Study NCT04245371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 1.8%
Description: Topical Patch
Study NCT04129554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-73763989
Description: JNJ-73763989 injection will be administered subcutaneously once every 4 weeks up to 48 weeks.
Study NCT04129554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56136379
Description: JNJ-56136379 tablets will be administered orally once daily up to 48 weeks.
Study NCT04129554 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for JNJ-73763989
Description: Matching placebo for JNJ-73763989 will be administered as subcutaneous injection up to 48 weeks.
Study NCT04129554 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for JNJ-56136379
Description: Matching placebo for JNJ-56136379 tablets will be administered orally up to 48 weeks.
Study NCT04129554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV) monohydrate
Description: ETV tablet will be administered orally once daily up to 48 weeks as NA treatment.
Study NCT04129554 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Entecavir (ETV) monohydrate
Description: ETV tablet will be administered orally once daily up to 48 weeks as NA treatment.
Study NCT04129554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Description: TDF will be administered orally once daily up to 48 weeks as NA treatment.
Study NCT04245371 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo Patch
Study NCT04129554 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tenofovir disoproxil fumarate (TDF)
Description: TDF will be administered orally once daily up to 48 weeks as NA treatment.
Study NCT04129554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide (TAF)
Description: TAF will be administered orally once daily up to 48 weeks as NA treatment.
Study NCT04129554 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tenofovir alafenamide (TAF)
Description: TAF will be administered orally once daily up to 48 weeks as NA treatment.
Study NCT03711357 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 980 nm diode laser
Description: 980 nm high power diode laser device.
Study NCT03711357 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: the diode laser fiber optic tip will be inserted in root canals, but will not be activated.
Study NCT02179151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZGN-440 for Injectable Suspension
Description: Subjects will receive ZGN-440 twice weekly subcutaneous injections for up to 28 weeks.
Study NCT03069469 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vimseltinib
Description: Colony-stimulating factor 1 receptor (CSF1R) inhibitor
Study NCT02179151 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ZGN-440 Placebo for Injectable Suspension
Description: Subjects will receive placebo twice weekly subcutaneous injections for up to 28 weeks.
Study NCT01861249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR339658
Description: Pharmaceutical form: Solution for infusion~Route of administration: Intravenous
Study NCT03201276 — intervention group
Intervention type: DRUG
Intervention: Glucosamine Sulfate
Description: Patients taking glucosamine sulfate 1500mg every day for at least four days.
Study NCT02972723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Oral Metformin 1g bd. (total = 2g per day) for 14 days
Study NCT00775359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate 160 mg tablets
Study NCT02473055 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kangaroo Care
Description: skin-to-skin, chest-to-chest placement of diaper clad preterm infant up against his mother's chest and covered by a receiving blanket folded into fourths for 2-3 hours from one feeding to the next.
Study NCT02024438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: monosialotetrahexosylganglioside Sodium
Description: it is extracted from pig's brain,shenjie is the brand name
Study NCT02024438 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: placebo
Description: saline of the same appearance as monosialotetrahexosylganglioside Sodium
Study NCT02929251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Anakinra (100 mg/day subcutaneously) (n=40) for 16 weeks
Study NCT02929251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab (162 mg/7 days subcutaneously) (n=40) for 16 weeks.
Study NCT02929251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Adalimumab (40mg/14 days subcutaneously) (n=40) for 16 weeks
Study NCT03767595 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProACT Adjustable Continence Therapy for Men
Description: The ProACT therapy consists of two small, adjustable silicone balloons connected with tubing to a port. During a minimally invasive outpatient procedure, the balloons are surgically placed in the area where the prostate was removed or resected.
Study NCT03724175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ursodiol (ursodeoxycholic acid, UDCA)
Description: ursodiol (ursodeoxycholic acid, UDCA) 300 mg two times daily for 10 weeks for UC pouchitis patients
Study NCT02691065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Integrase Inhibitor
Description: Raltegravir
Study NCT04506619 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.
Study NCT00695110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (TU) (300 mg T equivalents/dose)
Description: Three capsules each containing 100 mg testosterone (T) as TU, BID. 300 mg T equivalents BID 30 minutes after initiation of breakfast and dinner meals for 7 days. A 7-14 day washout period occurred between successive Treatment Periods.
Study NCT00695110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (400 mg T equivalents/dose)
Description: Two capsules each containing 100 mg T as TU and 100 mg T as TE, BID. 400 mg T equivalents BID 30 minutes after initiation of breakfast and dinner meals for 7 days. A 7-14 day washout period occurred between successive Treatment Periods.
Study NCT00695110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (TU) (200 mg T equivalents/dose with and without food)
Description: Two capsules each containing 100 mg T as TU, BID for 8 days. 200 mg T equivalents BID 30 minutes after initiation of meals (breakfast and dinner), except for Day 8 when the morning dose was administered fasting. A 7-14 day washout period occurred between successive Treatment Periods.
Study NCT00695110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (300 mg T equivalents/dose)
Description: Two capsules each containing 150 mg T as TU and 150 mg T as TE, BID. 300 mg T equivalents BID 30 minutes after initiation of breakfast and dinner meals for 7 days.
Study NCT03486197 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03486197 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT03486197 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo neutron radiation therapy
Study NCT03628924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab dose 1
Description: Participants will receive guselkumab dose 1 IV.
Study NCT03628924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab dose 2
Description: Participants will receive guselkumab dose 2 SC in Group 1, 2 and Group 3.
Study NCT03628924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab dose 3
Description: Participants will receive guselkumab dose 3 SC in Group 3.
Study NCT03628924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matched placebo SC and IV in group 1, 2 and 3 with an additional placebo SC dose in Group 3.
Study NCT06330831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive, Group Based Constraint Induced Therapy (CIMT)
Description: See arm description. Children who were in study 2 received two consecutive episodes of the intensive, group based CIMT intervention (episode 1 during the first summer, episode 2 during the following summer).
Study NCT01515358 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT01515358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3000328
Description: Administered orally
Study NCT01258387 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glial growth factor 2/ Neuregulin 1β3
Study NCT01258387 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04890756 — intervention group
Intervention type: OTHER
Intervention: observational
Description: The reliability was determined (n=100) by filling out the mBQ, two times, one week apart (test-retest).~For validation (n=45), the scores between the modified Baecke Questionnaire and the International Physical Activity Questionnaire were compared and the correlation between the modified Baecke Questionnaire and VO2max(via Astrand-Rhyming Cycle Ergometer Test) and between mBQ and interview (via METS) were assessed.
Study NCT02900027 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: APOC-III-L-Rx
Description: Ascending single and multiple doses of IONIS-APOC-III-LRx by subcutaneous (SC) injection
Study NCT02900027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Comparator
Description: Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator
Study NCT02641210 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal Treatment
Description: Periodontal Treatment using Gracey curettes and ultrasonic device.
Study NCT02641210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: All participants took Albendazole 400 mg before the intervention.
Study NCT01577732 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix-IPV+Hib™
Description: Single dose administered intramuscularly (IM) into the anterolateral side of the right thigh.